Literature DB >> 19623606

The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression.

Astrid Bjørnebekk1, Aleksander A Mathé, Stefan Brené.   

Abstract

One hypothesis of depression is that it is caused by reduced neuronal plasticity including hippocampal neurogenesis. In this study, we compared the effects of three long-term antidepressant treatments: escitalopram, voluntary running, and their combination on hippocampal cell proliferation, NPY and the NPY-Y1 receptor mRNAs, targets assumed to be important for hippocampal plasticity and mood disorders. An animal model of depression, the Flinders Sensitive Line (FSL) rat, was used and female rats were chosen because the majority of the depressed population is females. We investigated if these treatments were correlated to immobility, swimming, and climbing behaviors, which are associated with an overall, serotonergic-like and noradrenergic-like antidepressant response, in the Porsolt swim test (PST). Interestingly, while escitalopram, running and their combination increased the number of hippocampal BrdU immunoreactive cells, the antidepressant-like effect was only detected in the running group and the group with access both to running wheel and escitalopram. Hippocampal NPY mRNA and the NPY-Y1 receptor mRNA were elevated by running and the combined treatment. Moreover, correlations were detected between NPY mRNA levels and climbing and cell proliferation and NPY-Y1 receptor mRNA levels and swimming. Our results suggest that increased cell proliferation is not necessarily associated with an antidepressant effect. However, treatments that were associated with an antidepressant-like effect did regulate hippocampal levels of mRNAs encoding NPY and/or the NPY-Y1 receptor and support the notion that NPY can stimulate cell proliferation and induce an antidepressant-like response. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19623606     DOI: 10.1002/hipo.20683

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  23 in total

Review 1.  Depression, antidepressants, and neurogenesis: a critical reappraisal.

Authors:  Nicola D Hanson; Michael J Owens; Charles B Nemeroff
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Long-term suppression of forebrain neurogenesis and loss of neuronal progenitor cells following prolonged alcohol dependence in rats.

Authors:  Anita C Hansson; Kimberly Nixon; Roberto Rimondini; Ruslan Damadzic; Wolfgang H Sommer; Robert Eskay; Fulton T Crews; Markus Heilig
Journal:  Int J Neuropsychopharmacol       Date:  2010-03-25       Impact factor: 5.176

3.  Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Authors:  Thibault Renoir; Terence Y C Pang; Michelle S Zajac; Grace Chan; Xin Du; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Neuropeptide Y and posttraumatic stress disorder.

Authors:  R Sah; T D Geracioti
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

5.  Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT1A Expression and Emotional Behaviour of Male and Female Adolescent Rats.

Authors:  Lorena Henn; Natália C Zanta; Carlos Eduardo N Girardi; Deborah Suchecki
Journal:  Mol Neurobiol       Date:  2020-10-15       Impact factor: 5.590

Review 6.  The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward.

Authors:  Colleen M Novak; Paul R Burghardt; James A Levine
Journal:  Neurosci Biobehav Rev       Date:  2012-01-02       Impact factor: 8.989

7.  NPY intraperitoneal injections produce antidepressant-like effects and downregulate BDNF in the rat hypothalamus.

Authors:  Francesca Gelfo; Paola Tirassa; Paola De Bartolo; Nicoletta Croce; Sergio Bernardini; Carlo Caltagirone; Laura Petrosini; Francesco Angelucci
Journal:  CNS Neurosci Ther       Date:  2012-06       Impact factor: 5.243

8.  Neuropeptide Y protects rat cortical neurons against β-amyloid toxicity and re-establishes synthesis and release of nerve growth factor.

Authors:  Nicoletta Croce; Maria Teresa Ciotti; Francesca Gelfo; Silvia Cortelli; Giorgio Federici; Carlo Caltagirone; Sergio Bernardini; Francesco Angelucci
Journal:  ACS Chem Neurosci       Date:  2012-01-30       Impact factor: 4.418

9.  Diurnal fluctuations in HPA and neuropeptide Y-ergic systems underlie differences in vulnerability to traumatic stress responses at different zeitgeber times.

Authors:  Shlomi Cohen; Ella Vainer; Michael A Matar; Nitsan Kozlovsky; Zeev Kaplan; Joseph Zohar; Aleksander A Mathé; Hagit Cohen
Journal:  Neuropsychopharmacology       Date:  2014-09-22       Impact factor: 7.853

10.  Allele-specific programming of Npy and epigenetic effects of physical activity in a genetic model of depression.

Authors:  P A Melas; A Lennartsson; H Vakifahmetoglu-Norberg; Y Wei; E Åberg; M Werme; M Rogdaki; M Mannervik; G Wegener; S Brené; A A Mathé; C Lavebratt
Journal:  Transl Psychiatry       Date:  2013-05-07       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.